Research
Hormonal
GLP-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) reduce major adverse cardiovascular events (MACE) and heart failure hospitalizations in patients with type 2 diabetes, independent of glycemic control.
If you have Type 2 Diabetes and heart disease or high risk, ask your doctor about GLP-1 RAs or SGLT2is. These drugs protect your heart and kidneys, not just your blood sugar. They are often preferred over older medications like metformin if you have these risks.
StrongSupportsVERY_HIGH confidence
The development of GLP-1 RAs and SGLT2is has shifted T2D management by providing proven cardio-renal benefits in addition to glycemic control.
Why this rating
Supported by multiple large randomized controlled trials (LEADER, EMPA-REG, SOUL, SELECT).
Source
Pharmacologic Therapies for Type 2 Diabetes
Bryan Kuo et al. · NEJM Evidence · 2025
DOI 10.1056/evidra2400265
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status.Strong
- Tirzepatide, a dual GLP-1/GIP receptor agonist, provides greater HbA1c reduction and weight loss compared to semaglutide 1 mg in patients with Type 2 Diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →